Heterogeneity of kinase inhibitor resistance mechanisms in GIST

B. Liegl, I. Kepten, C. Le, M. Zhu, G. D. Demetri, Michael Heinrich, C. D M Fletcher, Christopher Corless, J. A. Fletcher

Research output: Contribution to journalArticle

257 Citations (Scopus)

Abstract

Most GIST patients develop clinical resistance to KIT/PDGFRA tyrosine kinase inhibitors (TKI). However, it is unclear whether clinical resistance results from single or multiple molecular mechanisms in each patient KIT and PDGFRA mutations were evaluated in 53 GIST metastases obtained from 14 patients who underwent surgical debulking after progression on imatinib or sunitinib. To interrogate possible resistance mechanisms across a broad biological spectrum of GISTs, inter- and intra-lesional heterogeneity of molecular drug-resistance mechanisms were evaluated in the following: conventional KIT (CD117)-positive GISTs with KIT mutations in exon 9, 11 or 13; KIT-negative GISTs; GISTs with unusual morphology; and KIT/PDGFRA wild-type GISTs. Genomic KIT and PDGFRA mutations were characterized systematically, using complementary techniques including D-HPLC for KIT exons 9, 11-18 and PDGFRA exons 12, 14, 18, and mutation-specific PCR (V654A, D820G, N822K, Y823D). Primary KIT oncogenic mutations were found in 11/14 patients (79%). Of these, 9/11 (83%), had secondary drug-resistant KIT mutations, including six (67%) with two to five different secondary mutations in separate metastases, and three (34%) with two secondary KIT mutations in the same metastasis. The secondary mutations clustered in the KIT ATP binding pocket and kinase catalytic regions. FISH analyses revealed KIT amplicons in 2/10 metastases lacking secondary KIT mutations. This study demonstrates extensive intra- and inter-lesional heterogeneity of resistance mutations and gene amplification in patients with clinically progressing GIST. KIT kinase resistance mutations were not found in KIT/PDGFRA wild-type GISTs or in KIT-mutant GISTs showing unusual morphology and/or loss of KIT expression by IHC, indicating that resistance mechanisms are fundamentally different in these tumours. Our observations underscore the heterogeneity of clinical TKI resistance, and highlight the therapeutic challenges involved in salvaging patients after clinical progression on TKI monotherapies.

Original languageEnglish (US)
Pages (from-to)64-74
Number of pages11
JournalJournal of Pathology
Volume216
Issue number1
DOIs
StatePublished - Sep 2008

Fingerprint

Phosphotransferases
Mutation
Protein-Tyrosine Kinases
Neoplasm Metastasis
Exons
Gene Amplification
Drug Resistance
Catalytic Domain
Adenosine Triphosphate
High Pressure Liquid Chromatography
Polymerase Chain Reaction

Keywords

  • Drug resistance mechanisms
  • GIST
  • Heterogeneity
  • Imatinib
  • Sunitinib

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Liegl, B., Kepten, I., Le, C., Zhu, M., Demetri, G. D., Heinrich, M., ... Fletcher, J. A. (2008). Heterogeneity of kinase inhibitor resistance mechanisms in GIST. Journal of Pathology, 216(1), 64-74. https://doi.org/10.1002/path.2382

Heterogeneity of kinase inhibitor resistance mechanisms in GIST. / Liegl, B.; Kepten, I.; Le, C.; Zhu, M.; Demetri, G. D.; Heinrich, Michael; Fletcher, C. D M; Corless, Christopher; Fletcher, J. A.

In: Journal of Pathology, Vol. 216, No. 1, 09.2008, p. 64-74.

Research output: Contribution to journalArticle

Liegl, B, Kepten, I, Le, C, Zhu, M, Demetri, GD, Heinrich, M, Fletcher, CDM, Corless, C & Fletcher, JA 2008, 'Heterogeneity of kinase inhibitor resistance mechanisms in GIST', Journal of Pathology, vol. 216, no. 1, pp. 64-74. https://doi.org/10.1002/path.2382
Liegl, B. ; Kepten, I. ; Le, C. ; Zhu, M. ; Demetri, G. D. ; Heinrich, Michael ; Fletcher, C. D M ; Corless, Christopher ; Fletcher, J. A. / Heterogeneity of kinase inhibitor resistance mechanisms in GIST. In: Journal of Pathology. 2008 ; Vol. 216, No. 1. pp. 64-74.
@article{43c092cbe7994ac88ebb5a2479fb7bd5,
title = "Heterogeneity of kinase inhibitor resistance mechanisms in GIST",
abstract = "Most GIST patients develop clinical resistance to KIT/PDGFRA tyrosine kinase inhibitors (TKI). However, it is unclear whether clinical resistance results from single or multiple molecular mechanisms in each patient KIT and PDGFRA mutations were evaluated in 53 GIST metastases obtained from 14 patients who underwent surgical debulking after progression on imatinib or sunitinib. To interrogate possible resistance mechanisms across a broad biological spectrum of GISTs, inter- and intra-lesional heterogeneity of molecular drug-resistance mechanisms were evaluated in the following: conventional KIT (CD117)-positive GISTs with KIT mutations in exon 9, 11 or 13; KIT-negative GISTs; GISTs with unusual morphology; and KIT/PDGFRA wild-type GISTs. Genomic KIT and PDGFRA mutations were characterized systematically, using complementary techniques including D-HPLC for KIT exons 9, 11-18 and PDGFRA exons 12, 14, 18, and mutation-specific PCR (V654A, D820G, N822K, Y823D). Primary KIT oncogenic mutations were found in 11/14 patients (79{\%}). Of these, 9/11 (83{\%}), had secondary drug-resistant KIT mutations, including six (67{\%}) with two to five different secondary mutations in separate metastases, and three (34{\%}) with two secondary KIT mutations in the same metastasis. The secondary mutations clustered in the KIT ATP binding pocket and kinase catalytic regions. FISH analyses revealed KIT amplicons in 2/10 metastases lacking secondary KIT mutations. This study demonstrates extensive intra- and inter-lesional heterogeneity of resistance mutations and gene amplification in patients with clinically progressing GIST. KIT kinase resistance mutations were not found in KIT/PDGFRA wild-type GISTs or in KIT-mutant GISTs showing unusual morphology and/or loss of KIT expression by IHC, indicating that resistance mechanisms are fundamentally different in these tumours. Our observations underscore the heterogeneity of clinical TKI resistance, and highlight the therapeutic challenges involved in salvaging patients after clinical progression on TKI monotherapies.",
keywords = "Drug resistance mechanisms, GIST, Heterogeneity, Imatinib, Sunitinib",
author = "B. Liegl and I. Kepten and C. Le and M. Zhu and Demetri, {G. D.} and Michael Heinrich and Fletcher, {C. D M} and Christopher Corless and Fletcher, {J. A.}",
year = "2008",
month = "9",
doi = "10.1002/path.2382",
language = "English (US)",
volume = "216",
pages = "64--74",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Heterogeneity of kinase inhibitor resistance mechanisms in GIST

AU - Liegl, B.

AU - Kepten, I.

AU - Le, C.

AU - Zhu, M.

AU - Demetri, G. D.

AU - Heinrich, Michael

AU - Fletcher, C. D M

AU - Corless, Christopher

AU - Fletcher, J. A.

PY - 2008/9

Y1 - 2008/9

N2 - Most GIST patients develop clinical resistance to KIT/PDGFRA tyrosine kinase inhibitors (TKI). However, it is unclear whether clinical resistance results from single or multiple molecular mechanisms in each patient KIT and PDGFRA mutations were evaluated in 53 GIST metastases obtained from 14 patients who underwent surgical debulking after progression on imatinib or sunitinib. To interrogate possible resistance mechanisms across a broad biological spectrum of GISTs, inter- and intra-lesional heterogeneity of molecular drug-resistance mechanisms were evaluated in the following: conventional KIT (CD117)-positive GISTs with KIT mutations in exon 9, 11 or 13; KIT-negative GISTs; GISTs with unusual morphology; and KIT/PDGFRA wild-type GISTs. Genomic KIT and PDGFRA mutations were characterized systematically, using complementary techniques including D-HPLC for KIT exons 9, 11-18 and PDGFRA exons 12, 14, 18, and mutation-specific PCR (V654A, D820G, N822K, Y823D). Primary KIT oncogenic mutations were found in 11/14 patients (79%). Of these, 9/11 (83%), had secondary drug-resistant KIT mutations, including six (67%) with two to five different secondary mutations in separate metastases, and three (34%) with two secondary KIT mutations in the same metastasis. The secondary mutations clustered in the KIT ATP binding pocket and kinase catalytic regions. FISH analyses revealed KIT amplicons in 2/10 metastases lacking secondary KIT mutations. This study demonstrates extensive intra- and inter-lesional heterogeneity of resistance mutations and gene amplification in patients with clinically progressing GIST. KIT kinase resistance mutations were not found in KIT/PDGFRA wild-type GISTs or in KIT-mutant GISTs showing unusual morphology and/or loss of KIT expression by IHC, indicating that resistance mechanisms are fundamentally different in these tumours. Our observations underscore the heterogeneity of clinical TKI resistance, and highlight the therapeutic challenges involved in salvaging patients after clinical progression on TKI monotherapies.

AB - Most GIST patients develop clinical resistance to KIT/PDGFRA tyrosine kinase inhibitors (TKI). However, it is unclear whether clinical resistance results from single or multiple molecular mechanisms in each patient KIT and PDGFRA mutations were evaluated in 53 GIST metastases obtained from 14 patients who underwent surgical debulking after progression on imatinib or sunitinib. To interrogate possible resistance mechanisms across a broad biological spectrum of GISTs, inter- and intra-lesional heterogeneity of molecular drug-resistance mechanisms were evaluated in the following: conventional KIT (CD117)-positive GISTs with KIT mutations in exon 9, 11 or 13; KIT-negative GISTs; GISTs with unusual morphology; and KIT/PDGFRA wild-type GISTs. Genomic KIT and PDGFRA mutations were characterized systematically, using complementary techniques including D-HPLC for KIT exons 9, 11-18 and PDGFRA exons 12, 14, 18, and mutation-specific PCR (V654A, D820G, N822K, Y823D). Primary KIT oncogenic mutations were found in 11/14 patients (79%). Of these, 9/11 (83%), had secondary drug-resistant KIT mutations, including six (67%) with two to five different secondary mutations in separate metastases, and three (34%) with two secondary KIT mutations in the same metastasis. The secondary mutations clustered in the KIT ATP binding pocket and kinase catalytic regions. FISH analyses revealed KIT amplicons in 2/10 metastases lacking secondary KIT mutations. This study demonstrates extensive intra- and inter-lesional heterogeneity of resistance mutations and gene amplification in patients with clinically progressing GIST. KIT kinase resistance mutations were not found in KIT/PDGFRA wild-type GISTs or in KIT-mutant GISTs showing unusual morphology and/or loss of KIT expression by IHC, indicating that resistance mechanisms are fundamentally different in these tumours. Our observations underscore the heterogeneity of clinical TKI resistance, and highlight the therapeutic challenges involved in salvaging patients after clinical progression on TKI monotherapies.

KW - Drug resistance mechanisms

KW - GIST

KW - Heterogeneity

KW - Imatinib

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=50249092801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249092801&partnerID=8YFLogxK

U2 - 10.1002/path.2382

DO - 10.1002/path.2382

M3 - Article

C2 - 18623623

AN - SCOPUS:50249092801

VL - 216

SP - 64

EP - 74

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -